0001209191-16-137674.txt : 20160817
0001209191-16-137674.hdr.sgml : 20160817
20160817194535
ACCESSION NUMBER: 0001209191-16-137674
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160815
FILED AS OF DATE: 20160817
DATE AS OF CHANGE: 20160817
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Pacira Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001396814
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 510619477
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5 SYLVAN WAY
STREET 2: SUITE 300
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
BUSINESS PHONE: 973-254-3560
MAIL ADDRESS:
STREET 1: 5 SYLVAN WAY
STREET 2: SUITE 300
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
FORMER COMPANY:
FORMER CONFORMED NAME: PACIRA INC
DATE OF NAME CHANGE: 20080318
FORMER COMPANY:
FORMER CONFORMED NAME: Blue Acquisition Corp
DATE OF NAME CHANGE: 20070418
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Scibetta James S
CENTRAL INDEX KEY: 0001383242
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35060
FILM NUMBER: 161839792
MAIL ADDRESS:
STREET 1: C/O BIOENVISION, INC.
STREET 2: 345 PARK AVENUE, 41ST. FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10154
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2016-08-15
0
0001396814
Pacira Pharmaceuticals, Inc.
PCRX
0001383242
Scibetta James S
C/O PACIRA PHARMACEUTICALS, INC.
5 SYLVAN WAY, SUITE 300
PARSIPPANY
NJ
07054
0
1
0
0
President
Common Stock
2016-08-15
4
M
0
9123
1.61
A
36207
D
Common Stock
2016-08-15
4
M
0
15877
1.61
A
52084
D
Common Stock
2016-08-15
4
S
0
25000
45.21
D
27084
D
Stock Option (Right to Buy)
1.61
2016-08-15
4
M
0
9123
0.00
D
2020-09-02
Common Stock
9123
0
D
Stock Option (Right to Buy)
1.61
2016-08-15
4
M
0
15877
0.00
D
2020-09-02
Common Stock
15877
22373
D
The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
Includes 330 shares of common stock acquired under the issuer's employee stock purchase plan in June 2016.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.82 to
$45.76, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and
Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in
this footnote 2.
The option vested as to 25% of the options on September 2, 2011 and vests as to the remaining options in successive equal monthly installments for the subsequent 36 months. The options became exercisable, to the extent vested, from and after the issuer's initial public offering.
The option vested as to 50% of the options on September 2, 2010 and vests as to the remaining options in successive equal monthly installments for the subsequent 24 months. The options become exercisable, to the extent vested, from and after the issuer's initial public offering.
/s/ James Scibetta
2016-08-17